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INTRODUCTION
In Korea, invasive uterine cervical cancer was ranked as the
fourth most common female cancer in 2002, although its
incidence is decreasing gradually (1). Radiotherapy with or
without chemotherapy using a combination of external beam
radiotherapy (EBRT) and intracavitary radiotherapy (ICR) is
an important treatment modality for any stage of cervical can-
cer. The role of ICR is to deliver a high dose of radiation direct-
ly to the tumor while sparing the adjacent normal tissues. ICR
has been performed by low-dose-rate (LDR) or high-dose-rate
(HDR) brachytherapy. Many centers have reported treatment
results, which show that the two modalities are comparable
(2, 3). HDR brachytherapy has advantages over LDR in that
staff is not exposed to a radiation hazard, the treatment time
is shorter, there is no need for hospitalization, no risk of anes-
thesia and thromboembolism, etc. Many centers in Korea have
adopted HDR brachytherapy and more than 70% of cervical
cancer patients referred for curative radiotherapy are treated
using HDR brachytherapy (4). Although many studies on
the use of HDR brachytherapy in cervix cancer are available
worldwide, the optimum treatment scheme remains unclear.
Moreover, because concurrent chemoradiotherapy is now viewed
as the standard treatment for locally advanced cervical cancer,
optimum HDR brachytherapy fractions, especially in com-
bination with chemotherapy, need to be settled urgently.
In 2000, the American Brachytherapy Society (ABS) pub-
lished its recommendations for the use of HDR brachytherapy
and recommended a range of 4 to 8 fractions (5). But they also
warned that these schedules had not been thoroughly tested
clinically and their use requires great caution. Much literature
is available regarding optimal fractionation regimens, but the
majority of studies have been retrospective (6-10). The results
of a Medline search showed that only one prospective random-
ized trial that compared two ICR fractionation regimens had
been undertaken (11). But, in the study, radiation doses were
not compared with the concept of a biological effective dose
(BED) (12, 13) and chemotherapy was not performed.
So, we performed a prospective randomized study and com-
pared two fractionation regimens of 3 Gy and 5 Gy of HDR
brachytherapy in cervical cancer patients treated by curative
radiotherapy with or without concurrent chemotherapy, and
tried to evaluate the toxicities and efficacies of these two reg-
imens with respect to biological effective doses at various re-
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A Prospective Randomized Study on Two Dose Fractionation
Regimens of High-Dose-Rate Brachytherapy for Carcinoma of the
Uterine Cervix: Comparison of Efficacies and Toxicities Between Two
Regimens
To evaluate the toxicities and efficacies of two fractionation regimens of high-dose-
rate brachytherapy in uterine cervical cancer, patients were stratified by stage Ib-
IIa versus IIb-IVa, and randomly assigned to receive 3 Gy fractions (group A) or 5
Gy fractions (group B). External radiotherapy was performed using a 10 MV radio-
graphy with a daily 1.8 Gy up to 30.6 Gy to the whole pelvis, and then with a mid-
line shield up to 45.0 Gy. Brachytherapy was performed with 3 Gy×10 times or 5
Gy×5 times, and this was followed by booster brachytherapy of a smaller fraction
to the residual tumor. Between August 1999 to July 2000, 46 patients were eligible.
Median follow-up period was 42 months (5-49). The range of age was 37-83 yr
(median, 58). The three-year disease-specific survival rates of group A (n=23) and
B (n=23) were 90.5%, 84.9%, respectively (p=0.64). The three-year pelvic control
rates of group A and B were 90.0% and 90.9%, respectively (p=0.92). The incidences
of late complications of the rectum or bladder of grade 2 or greater in groups A and
B were 23.8% and 9.1%, respectively (p=0.24). Our study showed that the results of
two regimens were comparable. Fractionation regimen using 5 Gy fractions seems
to be safe and effective, and offers shorter treatment duration.
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ference points.
MATERIALS AND METHODS
Study design
This study was designed as a prospective randomized study
conducted at the Chonnam National University Hospital.
From August 1999 to July 2000, patients with carcinoma of
the uterine cervix were enrolled in the study, and randomly
assigned to receive ICR fractionation regimens of fraction size
3 Gy or 5 Gy. These two fraction sizes were selected for the
following reasons. In Korea, the 5 Gy fraction is most com-
monly used, and the 3 Gy fraction is the smallest fraction used.
The latter may have more potential to spare normal tissue ra-
diobiologically, at the expense of more protracted fractionation.
Before randomization, patients were stratified according to
the International Federation of Gynecology and Obstetrics
(FIGO) as stage Ib-IIa or stage IIb-IVa. Other stratification
factors were not considered because of the relatively small
study sample size.
Patients population
Eligibility criteria consisted of a pathologically verified squa-
mous cell carcinoma or adenocarcinoma of the cervix, and an
Eastern Cooperative Oncology Group (ECOG) performance
status index of 0-2. The patients had no history of previous
malignancy, and hepatic, renal, and cardiopulmonary functions
were adequate. Pretreatment evaluation included a complete
medical history taking and a physical examination, and base-
line blood tests, chest radiography, sigmoidoscopy, cystoscopy,
and intravenous pyelography, and if necessary, computed to-
mography (CT) or magnetic resonance imaging (MRI) of the
abdomino-pelvis. Informed consents were obtained from all
patients, and the study protocol was approved by the institu-
tional review board of Chonnam National University Hospital.
External beam radiotherapy (EBRT)
Patients in each stratum of stage Ib-IIa and stage IIb-IVa
were assigned to either an ICR regimen of 3 Gy fractions
(Group A) or 5 Gy fractions (Group B) by using a computer
to randomly generate numbers. Prior to ICR, all patients under-
went EBRT to the whole pelvis. EBRT was performed using
a 10 MV linear accelerator using the 4-field box technique
in daily fractions of 1.8 Gy, 5 days per week. EBRT prior to
midline shield was delivered up to around 30.6 Gy over 3.5
weeks regardless of stage to allow a more controlled compar-
ison of cumulative BED. After ICR started, further EBRT
with midline shield was delivered on non-ICR weekdays up
to total dose of 45 Gy, and if necessary, a booster dose of 5.4-
14.4 Gy was delivered to the lateral pelvic wall.
Intracavitary radiotherapy (ICR)
Brachytherapy was performed by using a remotely controlled
afterloading system containing a high-dose-rate radioisotope
of 192Ir (Varisource
�, Varian, U.S.A.). A curved uterine tandem
and paired ovoids were used as applicators. Applicator inser-
tion was done on an outpatient basis with non-narcotic anal-
gesics. For ICR simulation, orthogonal radiography films of
anteroposterior and lateral view were taken with the applica-
tors inserted, and the position of rectum, bladder, and the A
point were defined according to ICRU 38 recommendations
(14). The reference points of the rectum and bladder were iden-
tified on films by inserting a Foley catheter balloon filled with
5 mL of contrast media and by filling the rectum with 50 mL
of barium. The rectal point dose was estimated at the anteri-
or rectal wall on a line from the middle of the ovoid sources.
ICR isodose curves were optimized by adjusting the dwell
times of a 5 mm-length stepping source at each position for
the three applicators. ICR was initially administered as a frac-
tion size of 3 Gy to the A point, 3 times a week in 10 fractions
(30 Gy) in group A, and 5 Gy twice a week in 5 fractions (25
Gy) in group B. This was planned as a similar total BED at
A point for both groups. At this time, follow-up gynecologi-
cal examinations or radiological studies, such as MRI, were
undertaken to assess tumor shrinkage. According to the mag-
nitude of the tumor regression and the resultant anatomical
changes of the uterus, a secondary ICR boost was performed
at a much smaller fraction size to A point as well as to the rec-
tal and bladder reference point, with sufficient coverage of
the residual tumor. This additional ICR boost was delivered
5 times in group A and 3 times in group B. The biological
effective dose was calculated by using a linear-quadratic model
with  / ratio of 10 for tumors and an  / ratio of 3 for the
rectum and bladder. When calculating BED, we did not con-
sider tumor repopulation during treatment. The equations
used for the BED calculation at each reference point were as
follows:
Total A point BED10=1.8*n1*(1+1.8/10)+ICRA*n2*
(1+ICRA/10)
Total rectal point BED3=1.8*n1*(1+1.8/3)+ICRR*n2*
(1+ICRR/3)
Total bladder point BED3=1.8*n1*(1+1.8/3)+ICRB*n2*
(1+ICRB/3)
n1: number of EBRT prior to midline shield 
n2: number of ICR fractions
ICRA: fraction size of A point in ICR
ICRR: fraction size of rectal reference point in ICR
ICRB: fraction size of bladder reference point in ICR
Concurrent chemotherapy
Chemotherapy was recommended in patients with adequate
hepatic, renal, and cardiopulmonary functions, who were diag-
nosed as FIGO Ib-IIa with a bulky tumor (greater than 4 cm)Brachytherapy for Carcinoma of the Uterine Cervix 89
or radiological pelvic lymphadenopathy, and in all patients
with FIGO IIb or greater. The chemotherapy agents used were
5-FU (1,000 mg/day for day 1-5, intravenous infusion) and
cisplatin (110 mg on day 1, intravenously). The timing of
chemotherapy was planned to start at the same time as the
external radiotherapy, and was repeated every 4 weeks for a
total of four courses.
Statistical methods
Each institution in Korea has different HDR equipment
and treatment policies, which makes it difficult to conduct
a multicenter study with an optimal sample size. Thus, we
conducted as a single institutional pilot study and enrolled
patients over a period of 12 months. The endpoints used to
compare the effect of the two fractionation regimens were
survival, pelvic tumor control, and complications. Toxicity
was assessed using the Radiation Therapy Oncology Group
(RTOG) grading system (15). Overall survival was defined
as the observed length of life from the date of protocol entry
to death or the last follow-up. Disease-specific survival was
calculated from the time of entry to death due to disease or
until the last follow-up. Patients who developed a central or
a pelvic relapse were considered as pelvic failures. We assessed
the tumor response 8 weeks after completing radiotherapy.
Patients were followed up every 2 months over the first year,
3 monthly during the next 3 yr, and then 6 monthly during
the subsequent years. Actuarial survival rates were calculated
using the Kaplan-Meier method, and differences between
survival curves were assessed using the log-rank test. Compar-
isons between categorical variables were based on the  2 test
or Fisher’ s exact test. Comparisons of continuous variables be-
tween independent groups were performed using the Mann-
Whitney U test. The Cox proportional hazards model was used
to assess the importance of various covariables. The Statistical
Package for the Social Sciences (SPSS) was used for statistical
analysis.
RESULTS
Patients and treatment characteristics
A total of 56 patients were enrolled between August 1999
and July 2000 and each treatment group included 28 patients
(Table 1). However, ten patients did not complete the planned
treatment. Of these, seven patients refused treatment and three
patients requested transfers to other hospitals. The resultant
total number of eligible patients was 46 with 23 patients in
each group. The median follow-up time was 42 months (range,
5-49 months) and the follow-up rate was 43/46 (93.5%) in
all patients, 21/23 in group A and 22/23 in group B. The age
range of all patients was 37-83 yr (median, 58 yr). The num-
bers of patients according to FIGO stage Ib1, Ib2, IIa, IIb, IIIa,
and IIIb were 8 (17.4%), 3 (6.5%), 10 (21.7%), 22 (47.8%),
1 (2.2%), and 2 (4.3%), respectively. Detailed data on patient
characteristics are listed in Table 2, and these characteristics
were not significantly different in the two groups. Radiolog-
ical lymphadenopathy (LAP) was defined as pelvic or paraaor-
tic lymph node (PAN) enlargement by CT or MRI. Maximum
tumor diameter was measured by CT or MRI. Detailed data
on treatment characteristics are listed in Table 3. Radiotherapy
duration and ICR number differed in the two groups because
of the protracted fractionation in group A. Six patients were
treated by ICR more than 15 times. In these patients, secondary
or even tertiary ICR boost sessions with much smaller frac-
tions were possible because rectal or bladder reference point
doses were negligible. One patient who had paraaortic LAP
was treated by extended field radiotherapy up to 45 Gy. Total
physical dose at the A point including EBRT and ICR seemed
to be larger in group A than in group B but the median total
BED10 at the A points were similar in the two groups.
Overall and disease-specific survival
The 3-yr overall survival rate (3YOSR) of all 46 patients
was 76.1% (Fig. 1). According to FIGO stage, the 3YOSRs
Patients Group A (3 Gy) Group B (5 Gy)
no. of patients
Total allocated number 28 28
Incomplete radiotherapy FIGO IIb: 2 FIGO Ib2: 1
FIGO IIIb: 3 FIGO IIb: 3
FIGO IVa: 1
Eligible patients 23 23
Complete follow-up 21 22
Table 1. Progress of patients through the study
Characteristics Group B
(n=23)
Group A
(n=23)
p-value
Age (yr)
median (range) 58 (43-72) 62 (37-83) 0.468
FIGO
Ib-IIa 12 9 0.695
IIb-III 11 14
Histology
SLNK* 11 15 0.569
SLK
� 55
SNOS
� 52
Adenoca. 2 1
Radiological LAP
�
pelvic 16 9 0.075
PAN
‖ 01
none 7 13
Maximum tumor diameter (cm)
median (range) 4.0 (1.5-5.5) 3.2 (1.7-6.0) 0.747
*SLNK, squamous large cell non-keratinizing type; 
� SLK, squamous large
cell. keratinizing type; 
� SNOS, squamous cell carcinoma not otherwise
specified; 
�LAP, lymphadenopathy; 
‖PAN, paraaortic lymph node.
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of Ib-IIa (n=21) and IIb-III (n=25) were 90.5% and 64.0%,
respectively (p=0.04, Fig. 2), and the 3YOSRs of groups A
and B were 78.3% and 73.9%, respectively (p=0.85, Fig. 3).
There was no significant difference in 3YOSRs by age (<60 yr
vs. ≥60), histology, tumor diameter (≤4 cm vs. >4), radi-
ological LAP (pelvic vs. paraaortic vs. none), radiotherapy dura-
tion (≤60 days vs. >60), total A point BED10 (≤110 Gy vs.
>110), or chemotherapy (yes vs. no). A total of 11 patients
died at the time of analysis, five patients from cervical cancer
and the other six patients without evidence of cervical cancer.
Thereby, the 3-yr disease-specific survival rate (3YDSSR) of
all patients was 87.8%. The 3YDSSRs of groups A and B were
90.5% and 85.0%, respectively (p=0.71, Fig. 4). According
to FIGO stage, the 3YDSSRs of Ib-IIa and IIb-III were 90.5%
and 84.9%, respectively (p=0.64).
Characteristics (Gy) Group B
(n=23)
Group A
(n=23)
p-value
median (range)
RT*duration (days) 65 (48-79) 58 (50-80) 0.043
No. of ICR
� 15 (11-17) 8 (7-10) 0.000
Whole pelvic dose 32.4 (27.0-41.4) 30.6 (25.2-39.6) 0.490
Total EBRT
�dose 54.0 (45.0-59.4) 54.0 (45.0-59.4) 0.785
ICR A point dose 36.5 (25.0-50.0) 33.0 (26.0-44.0) 0.084
Total A point dose 69.0 (55.6-80.6) 65.6 (54.2-78.2) 0.054
Total A point BED
�
10 110.0 (93.0-137.0) 110.0 (100.0-134.0) 0.428
Total rectal dose 63.2 (49.1-72.2) 55.1 (37.0-76.8) 0.606
Total rectal BED3 134.0 (95.8-176.4) 146.5 (105.2-192.0) 0.170
Total bladder dose 53.7 (44.7-66.8) 50.7 (36.4-70.2) 0.102
Total bladder BED3 117.3 (105.5-136.0) 118.2 (93.3-178.3) 0.886
Chemotherapy
yes n=17 (74%) n=15 (65%) 0.522
course 2 (1-5) 2 (1-4) 0.256
*RT, radiotherapy; 
� ICR, intracavitary radiotherapy; 
� EBRT, external beam.
radiotherapy; 
�BED, biologically effective dose.
Table 3. Treatment characteristics
Failures Ib-IIa
(n=21)
IIb-III
(n=22)
Group A
(n=21)
Group B
(n=22)
p-value p-value
PF* 0 1 (4.5) 1.000 0 1 (4.5) 1.000
PF+DM
� 1 (4.8) 2 (9.1) 1.000 2 (9.5) 1 (4.5) 0.607
DM 1 (4.8) 1 (4.5) 1.000 1 (4.8) 1 (4.5) 1.000
Total failure 2 (9.5) 4 (18.2) 0.664 3 (14.3) 3 (13.6) 1.000
*PF, pelvic failure; 
� DM, distant metastasis.
Table 4. Patterns of failure according to FIGO stage and group (%)
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Fig. 1. 3-yr overall survival (OS) and 3-yr disease-specific survival
(DSS) in all patients (n=46).
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Fig. 2. 3-yr overall survival according to the FIGO Ib-IIa (n=21) and
IIb-III (n=25).
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Fig. 3. 3-yr overall survival according to the group A (n=23) and
group B (n=23).
Characteristics Group B
(n=15)
Group A
(n=17)
p-value
Leukopenia 6 (35.3) 8 (53.3) ns
Neutropenia 1 (5.9) 2 (13.3) ns
Anemia 10 (58.8) 9 (60.0) ns
Abdominal pain 5 (29.4) 6 (40.0) ns
Diarrhea 5 (29.4) 5 (33.3) ns
Nausea/vomiting 2 (11.8) 3 (20.0) ns
Dysuria 3 (17.6) 1 (6.7) ns
None 7 (41.1) 6 (40.0) ns
ns: not significant.
Table 5. Incidence of acute complications of grade 0-2 in patients
treated with concurrent chemoradiotherapy (%)Failure patterns
Forty-five of 46 patients (97.8%) achieved an initial com-
plete response. Four patients (9.3%) developed pelvic failures
among 43 patients who were evaluable for tumor control (Table
4). In group A (n=21), two patients developed combined pelvic
and distant failures at 9 and 20 months, respectively; a 3-yr
pelvic control rate of 90.0% (Fig. 5). In group B (n=22), one
patient had local failure at 19 months and another patient devel-
oped combined failure at 18 months; a 3-yr pelvic control rate
of 90.9%. Distant metastasis developed in 5 patients, who
had all radiological lymphadenopathy. The sites of involve-
ment were the paraaortic lymph nodes in 2, lung in 2, and
one patient had both paraaortic and supraclavicular lymph
node metastasis. The two groups were not significantly dif-
ferent in terms of the total failure rate (Table 4).
Acute toxicity
Acute toxicities, which included hematologic profiles, were
evaluated mainly in patients who received concurrent chemo-
therapy. No patient showed grade 3 or 4 toxicity in terms of
the hematologic, gastrointestinal, or genitourinary systems.
All acute toxicities were relieved spontaneously or controlled
with minor medications (grade 1 or 2, Table 5). Unlike other
toxicities, anemia in our patients might reflect the effect of
cervical cancer per se, rather than treatment. The two groups
were similar in terms of the incidences of acute toxicities.
Late toxicity
Excluding three patients, for whom information regarding
late complications was unavailable, five of the 21 patients
(23.8%) in group A, and two of 22 (9.1%) in group B devel-
oped late complications, but this difference was not statisti-
cally significant, because of the small sample size (p=0.240).
In group A, all five patients developed grade 2 complications
(Table 6). In group B, one patient developed grade 2 rectal
bleeding and another patient combined rectovaginal and vesi-
covaginal fistulas of grade 4. The median delay for the occur-
rence of rectal complications was 16 months, whereas it was
21 months for bladder complications. The mean doses at vari-
ous reference points were compared in patients with or with-
out rectal complications of grade 2 or 4 in Table 7. As listed
in Table 7, ICR A point dose (40.5 Gy vs. 34.9 Gy, p=0.026)
and total A point BED10 (119 Gy vs. 110 Gy, p=0.042) were
significantly higher in patients with rectal complications. The
mean doses at reference points were compared in patients with
Brachytherapy for Carcinoma of the Uterine Cervix 91
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
 
r
a
t
e
Months
90.9%
p=0.92
90.0%
1.00
.80
.60
.40
.20
0.00
0 6 12 18 24 30 36 42 48
Fig. 5. 3-yr cumulative pelvic control rate according to the group
A (n=21) and group B (n=22).
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Fig. 4. 3-yr disease-specific survival according to the group A (n=
23) and group B (n=23).
No. Group Age (yr) FIGO Rectum ms* Bladder ms
ABED10
�
(Gy)
RBED3
�
(Gy)
BBED3
�
(Gy)
CTx
‖
1A5 8I b 2 bleeding 7 hematuria 21 137 166 133 +
2 A 47 IIb bleeding 13 -- 117 123 128 -
3 A 60 IIb bleeding 19 -- 111 150 109 +
4A6 1I b 1 bleeding 28 -- 104 144 107 -
5 A 65 IIa -- hematuria 10 111 114 122 +
6 B 51 IIIb bleeding 10 -- 123 192 141 +
7 B 46 IIb RVF
¶ 29 VVF** 29 125 143 178 -
*ms, months; 
� ABED, biologically effective dose at A point; 
� RBED, biologically effective dose at rectal reference point; 
�BBED, biologically effective
dose at bladder reference point; 
‖CTx, chemotherapy; 
¶RVF, rectovaginal fistula; **VVF, vesicovaginal fistula.
Table 6. Characteristics of patients with rectal or bladder late complications of grade 2 or 4 
Group A
Group B
Group A
Group Bor without bladder complications of grade 2 or 4 in Table 8.
As listed in Table 8, ICR A point dose (43.8 Gy vs. 35.1 Gy,
p=0.022) and total bladder point BED3 (144 Gy vs. 117 Gy,
p=0.045) were significantly higher in patients with bladder
complications.
DISCUSSION
The use of HDR brachytherapy for the treatment of uter-
ine cervix cancer has been increasing worldwide. Radiobio-
logical aspects are mentioned in the literatures in terms of
advantages or disadvantages of HDR brachytherapy versus
LDR (16, 17). A better optimization of HDR brachytherapy
dose distribution seems to be one of the important advantages.
The variation of dwell time of single stepping sources in HDR
brachytherapy permits an almost infinite variation of effective
source strength. Many centers have reported treatment results
and concluded that the results of LDR and HDR are compa-
rable (2, 3). Our results concur with the literature in terms of
survivals, failure patterns, and late complications. Although
HDR brachytherapy has been used for more than 30 yr, there
is still no consensus about the optimum fractionation sched-
ule for the treatment of cervical cancer, and this varies widely
in clinical practice. The ABS survey of brachytherapy practice
for carcinoma of the cervix in the U.S.A. showed that the medi-
an HDR brachytherapy dose was about 30 Gy and that the
median dose per fraction was 6 Gy for a median of 5 fractions
(18). In our country, most centers use a fraction size of 3 to
5 Gy with a range of 5 to 13 fractions (4).
So far, only one prospective randomized study has attempt-
ed to determine the effects of different fractionations (11). This
study found no differences in terms of treatment results or in
the incidence of late complications between fraction sizes of
7.5 Gy and 6 Gy, which suggests that a small number of frac-
tions (7.5 Gy/fraction) might be advantageous, because of the
shorter duration and a lower treatment load. Petereit et al.
(19) reviewed 24 articles on HDR brachytherapy for cervical
cancer using different regimens, but failed to identify an opti-
mal fractionation schedule. They observed that the technique
and experience of individual centers might have played a more
important role than attempts to optimize fractionation. From
the radiobiological point of view, simple comparisons of var-
ious fraction sizes and total physical doses of ICR used in dif-
ferent studies might lead to incorrect interpretations, in addi-
tion, doses of EBRT to the whole pelvis also differ widely in
studies. This is why the interpretation of optimal fraction size
or total doses of ICR of HDR brachytherapy are difficult. Since
the concept of BED was accepted in the clinical field, some
have reported upon the results of various combinations of
EBRT and ICR fractionations in terms of BED10 or BED3. Nag
and Gupta (20) developed and published a simple Excel spread-
sheet program to assist clinicians in the calculation of equiv-
alent HDR brachytherapy regimen doses. Although we did
not publish at that time, we also developed calculation sheets
in terms of BED10 or BED3 for various combinations of EBRT
and ICR fractionations using Excel, and converted BED into
total equivalent doses applied as 1.8 Gy fractions, to allow more
practical comparisons with conventional fractionation.
Many studies have been reported upon the acceptable BED
of reference points. Lee et al. (6) reported upon the results of
brachytherapy using a 3 Gy fraction size, and recommended
that rectal BED3 should be kept below 130 Gy. Clark et al.
(21) found a dose response relationship and a threshold for late
rectal complications above 125 Gy3 at rectal reference point,
in a study involving concurrent chemoradiotherapy. Ferrigno
et al. (8) reported that the 5-yr late bladder complication rate
was higher among patients treated with BED of larger than
125 Gy3 at bladder reference point, although the difference
was not statistically significant (17% vs. 9%, p=0.27). Toita
et al. (22) suggested that the rectal BED3should be kept below
100-120 Gy. Ogino et al. (23) reported that no grade 4 rectal
complication was observed in any patient with a time-dose
factor (TDF) below 130 or a BED below 147. In our study,
the mean rectal BED3 of patients with grade 2-4 complica-
tions was above 150 Gy, although no significant difference
was found between these patients and those with lower grade
complications. Mean bladder BED3 of our patients with grade
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Characteristics (Gy) Grade 2-4
(n=6)
Grade 0-1
(n=37)
p-value
Whole pelvic dose 32.8 33.0 0.741
Total EBRT* dose 53.1 54.9 0.325
ICR
�A point dose 34.9 40.5 0.026
Total A point dose 67.7 73.5 0.068
Total A point BED
�
10 110.1 119.5 0.042
Total rectal dose 58.5 65.2 0.119
Total rectal BED3 136.3 152.9 0.132
Chemotherapy n=27 (73%) n=3 (50%) 0.345
*EBRT, external beam radiotherapy; 
� ICR, intracavitary radiotherapy;
� BED, biologically effective dose.
Table 7. Mean doses at various reference points according to
subgroups of late rectal complications
Characteristics (Gy) Grade 2-4
(n=3)
Grade 0-1
(n=40)
p-value
Whole pelvic dose 33.0 30.6 0.230
Total EBRT* dose 53.2 54.6 0.692
ICR
�A point dose 35.1 43.8 0.022
Total A point dose 68.0 74.4 0.153
Total A point BED
�
10 110.5 124.3 0.053
Total bladder dose 52.3 59.1 0.190
Total bladder BED3 117.8 144.6 0.045
Chemotherapy n=28 (70%) n=2 (66.7%) 1.000
*EBRT, external beam radiotherapy; 
� ICR, intracavitary radiotherapy;
� BED, biologically effective dose.
Table 8. Mean doses at various reference points according to
subgroups of late bladder complications2-4 complications was above 140 Gy and this differed signifi-
cantly from those with lower grade complications.
It is difficult to compare late complication rates with those
of other studies, because of the different grading systems adopt-
ed, and the different follow-up periods used. Fu and Phillips
(2) reviewed the treatment results of HDR brachytherapy in
the literature. Major rectal and bladder complication rates
ranged from 1.4% to 10% and from 0.3% to 4%, respective-
ly. Our study also showed comparable results. However, the
relationship between reference rectal and bladder points doses
defined by ICRU 38 and the incidence of late complications
has not always been accepted. A recent survey upon the use
of the ICRU 38 reference point showed that rectum and blad-
der ICRU points were recorded in only 55% and 58%, respec-
tively, in clinical practice (24). Moreover, those two points were
reported in only 18% and 14%, respectively, in literature. The
study concluded that comprehensive concepts were needed
for reporting dose to points and volumes in target and criti-
cal organs. Kapp et al. (25) failed to find a correlation between
the maximum doses to the rectum, bladder and the A point,
and the development of late sequelae. They concluded that
threshold doses for normal tissue in HDR brachytherapy could
not be determined by considering doses at single points. In
our study, the bladder reference point had a greater predictive
value for late complications than the rectal reference point.
The current tendency is to consider the volume and dose to
organs irradiated, rather than a single point that is presumed
to receive a maximum dose (26). Using CT-based brachyther-
apy planning, Uno et al. (27), in an analysis of 100 patients
with stages IIb or IIIb cervical cancer treated with HDR brac-
hytherapy, found that the depth of the 6-Gy isodose volume
determined three dimensionally has a predictive value in terms
of late rectal complications.
Recently, several randomized trials have shown that better
treatment results are obtained using concurrent chemoradio-
therapy (28-30), but information regarding concurrent chemo-
radiotherapy with HDR brachytherapy is scarce, because most
experiences of combining chemotherapy and brachytherapy
have been based on LDR treatment. Our current treatment
policy is to use concurrent chemoradiotherapy for high-risk
early stage, or stage IIb or greater patients. Our results show
that the acute side effects are tolerable in patients treated with
chemoradiotherapy and that late complications are similar,
regardless of the use of chemotherapy. The 3 Gy fraction size
used in our study is one of the smallest used in Korea, and was
adopted to maximize biological advantages compared to 5 Gy.
However, this prolongs the overall treatment time, which may
directly affect the tumor control rate. Our patients in the 3 Gy
fraction arm were treated for a median 65 days, which was
seven days longer than those in the 5 Gy arm. Although fail-
ure patterns were not different in the two groups in our study,
if more patients had been enrolled or the follow-up extend-
ed, both groups may have revealed different failure patterns.
In conclusion, our results showed that the two HDR frac-
tionations were comparable in view of survival, failure patterns,
and late complications. The development of late complica-
tions was found to depend on the absolute BED at each ref-
erence point rather than the fraction size. The fractionation
regimen involving a 5 Gy fraction size and application twice
a week seems to be both safe and effective for the treatment of
uterine cervical cancer, and offers a shorter treatment duration.
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